Table 1 Association between CRC patient characteristics and miR-760 expression
From: MiR-760 suppresses human colorectal cancer growth by targeting BATF3/AP-1/cyclinD1 signaling
Pathological variables | Number of patients in each group | MiR-760 expression | p valuea | |
|---|---|---|---|---|
Low | High | |||
All cases | 76 | 38 | 38 | |
Ages | 0.16867 | |||
<  60 | 38 | 16 (42%) | 22 (58%) | |
≧ 60 | 38 | 22 (58%) | 16 (42%) | |
Gender | 0.06046 | |||
Male | 46 | 19 (41%) | 27 (59%) | |
Female | 30 | 19 (63%) | 11 (37%) | |
Dukes stage | 0.03726 | |||
A + B | 43 | 17 (40%) | 26 (60%) | |
C + D | 33 | 21 (64%) | 12 (36%) | |
Liver Metastasis | 0.17467 | |||
M0 | 66 | 35 (53%) | 31 (47%) | |
M1 | 10 | 3 (30%) | 7 (70%) | |
Cancer Type | 0.15364 | |||
Colon | 28 | 11 (39%) | 17 (61%) | |
Recta | 48 | 27 (56%) | 21 (44%) | |
Lymph Node Metastasis | 0.03567 | |||
N0 | 45 | 18 (40%) | 27 (60%) | |
N1 | 31 | 20 (65%) | 11 (35%) | |
Preoperative serum CEA level | 0.24319 | |||
< 5 μg/mL | 45 | 20 (44%) | 25 (56%) | |
≥ 5 μg/mL | 31 | 18 (58%) | 13 (42%) | |